Charles River Laboratories exercised its option to acquire the remaining 79% of PathoQuest and agreed to buy assets of K.F. (Cambodia) to strengthen NGS‑based biologics QC and nonhuman primate supply chains — transactions totaling roughly $570 million. Charles River said the deals bolster GMP testing and secure NHP supply. Separately, Asimov and AGC Biologics agreed a license to deploy Asimov’s LV Edge Packaging cell line for lentiviral production at AGC’s Milan CDMO site, aiming to simplify LV manufacturing from a four‑plasmid to single‑plasmid workflow and lower GMP plasmid costs.